RPG Lifesciences, formerly known as Searle (India) is a pharma company producing a wide range of quality and affordable medicines in Global Generics and Synthetic APIs, is in the limelight today, post its turnaround performance for Q4FY15.

Breaching the 10% upper circuit the moment it opened at Rs.154.40, the stock is currently at 152 levels, around 8% up. Volumes are up almost 2 times.

The company posted a net profit of Rs.5 crore compared to loss of Rs.51 lakh in Q4FY14. Sequentially, the net profit has risen 68%. Net sales was up 21% at Rs.61 crore. Costs have risen 15% mainly on the back of a 13% jump in employee benefits, 10% rise in other expenses though raw material fell 9%.